% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reinhard:300116,
      author       = {S. Reinhard and J. S. Utikal$^*$ and A. Zaremba$^*$ and G.
                      Lodde$^*$ and I. von Wasielewski and K. C. Klespe and F.
                      Meier and S. Haferkamp and K. C. Kähler and R. Herbst and
                      C. Gebhardt and A. Sindrilaru and E. Dippel and Y. Angela
                      and P. Mohr and C. Pfoehler and A. Forschner and M. Kaatz
                      and B. Schell and A. Gesierich and C. Loquai and J. C.
                      Hassel and J. Ulrich and F. Meiss and G. Schley and L. M.
                      Heinzerling and M. Sachse and J. Welzel and C. Weishaupt and
                      C. Sunderkötter and C. Michl and H.-H. Lindhof and A.
                      Kreuter and M. V. Heppt and S. Wenk and C. Mauch and C.
                      Berking and A. S. Nedwed and R. Gutzmer and U. Leiter and D.
                      Schadendorf and S. Ugurel and M. Weichenthal and M. Haist
                      and M. I. Fleischer and B. Lang and S. Grabbe and H. Stege},
      title        = {{F}irst-line checkpoint inhibitor therapy in metastatic
                      acral lentiginous melanoma compared to other types of
                      cutaneous melanoma: {A} multicenter study from the
                      prospective skin cancer registry {ADOREG}.},
      journal      = {European journal of cancer},
      volume       = {220},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00614},
      pages        = {115356},
      year         = {2025},
      abstract     = {Melanoma is the main cause of skin cancer-related death.
                      Treatment with immune checkpoint inhibitors (CPI) has
                      improved the prognosis in recent years. However, subtypes of
                      melanoma differ in their response. Acral lentiginous
                      melanoma (ALM) has a worse prognosis compared to cutaneous
                      melanoma other than ALM (CM) and is therefore of particular
                      relevance.To evaluate the efficacy of CPI in first-line
                      treatment of patients with advanced ALM compared
                      CM.Retrospective analysis of patients with metastatic ALM (n
                      = 45) or CM (n = 328) who received first-line CPI therapy
                      from the multicenter prospective skin cancer registry
                      ADOREG. Study endpoints were best overall response (BOR),
                      progression-free survival (PFS) and overall survival
                      (OS).ALM patients had significantly higher rates of
                      ulcerated tumors, loco regional metastases and fewer
                      BRAF-mutated tumors compared to CM patients. Combined CPI
                      was administered in 48.9 $\%$ ALM patients and 39.3 $\%$ of
                      CM patients, while the remaining patients received PD-1
                      monotherapy. OS trended to be shorter in patients with ALM
                      (18.1 vs. 43.8 months, p = 0.10) with no significant
                      differences in PFS (7.0 vs. 11.5 months, p = 0.21). In
                      patients with CM, median OS with combined CPI was not
                      reached, whereas the median OS after PD-1 monotherapy was
                      37.8 months (p = 0.22). Conversely, in patients with ALM, OS
                      with combined CPI was 17.8 months, compared to 26 months
                      with PD-1 monotherapy (p = 0.15). There were no significant
                      differences in BOR between patients with ALM or CM.Analysis
                      of this real-world cohort of patients with metastatic
                      melanoma showed a trend towards poorer survival outcomes
                      upon first-line treatment with CPI in ALM compared to
                      cutaneous melanoma of other subtypes.},
      keywords     = {Checkpoint inhibition (Other) / Melanoma (Other) / Response
                      (Other)},
      cin          = {A370 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)A370-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40121837},
      doi          = {10.1016/j.ejca.2025.115356},
      url          = {https://inrepo02.dkfz.de/record/300116},
}